Last reviewed · How we verify
NOVOCART® Inject plus
NOVOCART® Inject plus is an autologous chondrocyte implantation therapy that delivers cultured patient cartilage cells directly into cartilage defects to promote tissue regeneration.
NOVOCART® Inject plus is an autologous chondrocyte implantation therapy that delivers cultured patient cartilage cells directly into cartilage defects to promote tissue regeneration. Used for Symptomatic articular cartilage defects of the knee.
At a glance
| Generic name | NOVOCART® Inject plus |
|---|---|
| Sponsor | Tetec AG |
| Drug class | Autologous cell therapy |
| Modality | Small molecule |
| Therapeutic area | Orthopedics / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
The drug consists of autologous (patient-derived) chondrocytes suspended in a fibrin matrix that is injected directly into articular cartilage lesions. The chondrocytes integrate into the defect site and produce extracellular matrix components, promoting repair and regeneration of damaged hyaline cartilage. This approach aims to restore cartilage structure and function while reducing pain and improving joint mobility.
Approved indications
- Symptomatic articular cartilage defects of the knee
Common side effects
- Joint swelling
- Joint pain
- Effusion
- Infection at injection site
Key clinical trials
- NOVOCART® Inject Plus for Cartilage Defects of the Knee (PHASE3)
- Observational Study With NOVOCART® Inject in the Reconstruction of the Hip Joint With Full Thickness Cartilage Defects
- Non-interventional Study With NOVOCART® Inject in the Reconstruction of the Knee Cartilage Defects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |